Abstract
The authors assessed the effect of IV abciximab on early neurologic improvement and ischemic lesion growth in 29 patients with supratentorial stroke and NIH stroke scale score (NIHSSS) > or = 4 (11.1 +/- 5.9), treated within 3 to 24 (13.6 +/- 5.5) hours of onset. The 48 to 72-hour NIHSSS improvement was 4.4 +/- 3.2 and the 24-hour lesion growth on DWI was +23% (-50%, +103%); 7/26 (27%) patients experienced lesion size decrease. Treatment of sub-24-hour stroke with abciximab improves early post-treatment neurologic status and often attenuates ischemic lesion growth.
Publication types
-
Clinical Trial
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Abciximab
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal / adverse effects
-
Anticoagulants / administration & dosage*
-
Anticoagulants / adverse effects
-
Brain / drug effects*
-
Brain / pathology
-
Brain / physiopathology
-
Brain Ischemia / diagnosis
-
Brain Ischemia / drug therapy*
-
Brain Ischemia / physiopathology
-
Cerebral Arteries / drug effects
-
Cerebral Arteries / pathology
-
Cerebral Arteries / physiopathology
-
Female
-
Humans
-
Immunoglobulin Fab Fragments / administration & dosage*
-
Immunoglobulin Fab Fragments / adverse effects
-
Infusions, Intravenous
-
Intracranial Hemorrhages / chemically induced
-
Intracranial Hemorrhages / pathology
-
Intracranial Hemorrhages / physiopathology
-
Magnetic Resonance Imaging
-
Male
-
Middle Aged
-
Patient Selection
-
Stroke / diagnosis
-
Stroke / drug therapy*
-
Stroke / physiopathology
-
Time Factors
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Anticoagulants
-
Immunoglobulin Fab Fragments
-
Abciximab